RhythmAnalytics vs Tempus ECG-AF
AI Verdict
Choose RhythmAnalytics if…
Choose RhythmAnalytics if your primary need is automated, real-time or near real-time interpretation of various cardiac arrhythmias from single-lead ECG data. This tool is ideal for integrating with continuous monitoring devices or wearable sensors to provide immediate clinical decision support for active arrhythmia detection and management.
View RhythmAnalytics →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify patients aged 65 or older at a higher risk of developing new-onset atrial fibrillation within the next year. This solution is best suited for integrating with existing 12-lead ECG workflows to enable earlier risk stratification and facilitate timely follow-up for preventative care.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | RhythmAnalytics | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact vendor | Contact vendor |
| Deployment | Cloud-based API | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
RhythmAnalyticsTool A, RhythmAnalytics, is described as a 'Cloud-based API' and is compatible with a broader range of input sources including Holter, event recorders, and wearable sensors. This suggests greater flexibility and potential for seamless integration into diverse clinical workflows and monitoring scenarios. While Tool B also integrates into healthcare systems, its focus on 12-lead ECGs from specific vendors might imply a narrower scope of application.
Clinical Value
RhythmAnalyticsRhythmAnalytics (Tool A) offers immediate, comprehensive diagnostic interpretation for over 15 types of cardiac arrhythmias from single-lead ECG data, providing direct clinical decision support across various acute and chronic care settings. Tempus ECG-AF (Tool B) provides predictive risk assessment for future AFib development in a specific demographic, which is valuable for proactive management but has a more focused clinical application compared to Tool A's broad diagnostic utility.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly states the availability of CMS reimbursement with specific CPT codes and a Medicare rate, effective January 1, 2025. This transparency and established reimbursement pathway significantly enhance its value proposition for healthcare providers, making it easier to justify costs and integrate into billing. RhythmAnalytics (Tool A) only states 'contact vendor' for pricing, without any details on reimbursement.
Enterprise Readiness
Tempus ECG-AFBoth tools are FDA-cleared and HIPAA compliant. However, Tempus ECG-AF (Tool B) explicitly states 'has_baa: yes', which is a crucial legal agreement for healthcare enterprises handling protected health information. RhythmAnalytics (Tool A) lists 'has_baa: unspecified', which, while potentially covered by its HIPAA compliance, lacks the explicit confirmation that Tool B provides, giving Tool B a slight edge in demonstrating enterprise readiness.
Innovation
Tempus ECG-AFWhile both tools leverage AI for ECG analysis, Tempus ECG-AF (Tool B) demonstrates a distinct innovation by focusing on predictive risk assessment for future Atrial Fibrillation development in a specific patient population. This shifts the paradigm from reactive diagnosis to proactive prevention and early intervention. RhythmAnalytics (Tool A) provides comprehensive real-time diagnostic interpretation, which is valuable but represents a more established application of AI in cardiology.
Support & Docs
TieNeither the provided structured facts nor readily available public web search results offer specific details regarding the quality, availability, or channels for support and documentation for either RhythmAnalytics or Tempus ECG-AF. Without this information, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | RhythmAnalytics | Tempus ECG-AF |
|---|---|---|
| Name | RhythmAnalytics | Tempus ECG-AF |
| Company | Biofourmis Singapore Pte. | Tempus AI, Inc. |
| Input ECG Type | Single-lead ECG data; compatible with FDA-cleared ECG devices (Holter, event recorders, wearable sensors) | 12-lead ECG recordings; compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems |
| Primary Focus/Detection | Automated interpretation of cardiac arrhythmias (over 15 types including AFib, ventricular arrhythmias, ectopic beats) | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months |
| Target Patient Population | Not specified | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery |
Videos
Demos, reviews, and walkthroughs featuring RhythmAnalytics and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring RhythmAnalytics or Tempus ECG-AF
Backers
Who funded each tool's parent company.